What is HC Wainwright’s Estimate for CORT FY2030 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at HC Wainwright lowered their FY2030 EPS estimates for Corcept Therapeutics in a research note issued to investors on Wednesday, February 25th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of $7.19 for the year, down from their previous forecast of $7.74. HC Wainwright has a “Buy” rating and a $67.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). The firm had revenue of $202.13 million during the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. Corcept Therapeutics’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.26 EPS.

Several other research analysts have also recently weighed in on CORT. Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research report on Wednesday, December 31st. Truist Financial set a $50.00 price objective on shares of Corcept Therapeutics in a research note on Wednesday, December 31st. Finally, Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a report on Friday, January 23rd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $77.17.

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $35.70 on Thursday. The stock has a 50 day simple moving average of $44.41 and a 200 day simple moving average of $65.77. The stock has a market cap of $3.80 billion, a P/E ratio of 43.54 and a beta of 0.25. Corcept Therapeutics has a 1-year low of $28.66 and a 1-year high of $117.33. The company has a current ratio of 2.92, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its holdings in shares of Corcept Therapeutics by 546.9% in the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after purchasing an additional 1,274,215 shares in the last quarter. Norges Bank acquired a new position in shares of Corcept Therapeutics during the 2nd quarter worth $72,048,000. Epoch Investment Partners Inc. bought a new stake in shares of Corcept Therapeutics during the 2nd quarter worth $56,181,000. Geode Capital Management LLC boosted its stake in Corcept Therapeutics by 38.0% in the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock valued at $92,892,000 after buying an additional 734,646 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Corcept Therapeutics by 223.4% in the third quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock valued at $70,632,000 after buying an additional 587,053 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Corcept Therapeutics news, CEO Joseph K. Belanoff sold 40,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $79.77, for a total value of $3,190,800.00. Following the transaction, the chief executive officer directly owned 2,701,370 shares of the company’s stock, valued at $215,488,284.90. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.52, for a total transaction of $1,590,400.00. Following the completion of the transaction, the insider owned 7,904 shares of the company’s stock, valued at $628,526.08. The trade was a 71.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 125,000 shares of company stock valued at $8,301,450. Corporate insiders own 20.80% of the company’s stock.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: HC Wainwright keeps a constructive stance — the firm retained a “Buy” rating and a $67 price target and revised some near-term quarterly EPS forecasts upward (Q1–Q3 adjustments), providing continued analyst support for the story. HC Wainwright Research Note
• Neutral Sentiment: Short-interest report shows no meaningful reported short position (entry shows 0 shares / 0.0 days), so today’s move is unlikely driven by short-covering or a jump in new short activity. (Data in the filing appears anomalous.)
• Neutral Sentiment: Market commentary and analysis pieces question whether current pricing fully reflects the stock’s steep one‑year decline and ongoing operational risks — useful background but not an immediate catalyst. Is Corcept Pricing Reflect Its Decline (Yahoo)
• Neutral Sentiment: Post‑earnings coverage and summaries highlight a mixed picture from the Q4 call (growth but rising risks); these recaps inform investor expectations but are not new filings. TipRanks Earnings Recap
• Negative Sentiment: Multiple securities class‑action suits and dozens of plaintiff‑solicitation notices were announced this week, alleging securities law violations for the period Oct 31, 2024–Dec 30/31, 2025. Several national firms are seeking lead plaintiffs (April 21, 2026 deadline), creating legal overhang, potential defense costs and settlement risk. Rosen Law Firm Notice Hagens Berman Alert
• Negative Sentiment: HC Wainwright lowered medium‑ and long‑term earnings forecasts (FY2026–FY2030 cuts across multiple years), signaling reduced analyst expectations for structural revenue/profitability growth; downward revisions can pressure valuation and investor confidence despite the maintained Buy rating. HC Wainwright Estimates Update

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.